Dr Reddy’s announced a price reduction of its cardiovascular drug Cidmus. It is a pharma composition containing a combination of sacubitril and valsartan, indicated for heart failure patients with reduced ejection fraction, the company notified in a statement yesterday.
Dr Reddy’s Cidmus tablets are available in three strengths – 50 mg, 100 mg and 200 mg, to be taken twice a day. Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs 78.32), Rs 49 for 100 mg (down from Rs 83.86) and Rs 79 for 200 mg (down from Rs 96.71) per tablet. The product will be manufactured in-house. The Active Pharmaceutical Ingredient (API) of Cidmus is manufactured at a United States Food and Drug Administration (USFDA)-approved facility. The tablets have a co-crystal formulation that enhances bioavailability, solubility and physical and chemical properties of the drug, the statement said.
It further noted that Cidmus is part of a portfolio of medicines offered to patients in the cardiovascular segment by Dr Reddy’s alongside its brands such as Stamlo, Stamlo Beta, Reclide-XR and Reclimet-XR. This price reduction will further widen.
Dr Reddy’s acquired the cardiovascular brand Cidmus from Novartis AG in 2022 for the India market. Driven by the company’s strong marketing and distribution network, Cidmus has reached more than one lakh patients in India with a market share of 32 per cent, concluded the statement.